| Spiro B Antoniades, MD | |
|
2014 S Tollgate Rd Ste 107, Bel Air, MD 21015-6010 | |
| (410) 446-8747 | |
| (443) 643-2088 |
| Full Name | Spiro B Antoniades |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 32 Years |
| Location | 2014 S Tollgate Rd Ste 107, Bel Air, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265535512 | NPI | - | NPPES |
| 032500700 | Medicaid | MD | |
| F 482 / 001 | Other | MD | BLUE CHOICE |
| LZ51/546417-06, 07, | Other | MD | BS / BC OF MD |
| LZ51/546417-08, 09 | Other | MD | BC /BS OF MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | D0047688 (Maryland) | Secondary |
| 207XS0117X | Orthopaedic Surgery - Orthopaedic Surgery Of The Spine | D0047688 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Agnes Hospital | Baltimore, MD | Hospital |
| University Of Md Harford Memorial Hospital | Havre de grace, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Agape Physical Therapy And Sports Rehabilitation Lp | 3870741390 | 147 |
| St. Agnes Healthcare, Inc. | 9830092733 | 237 |
News Archive
The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
In findings never before seen in melanoma, a novel combination therapy was found to be highly effective at treating patients with skin metastases, new research from UC Davis has shown.
Protalix BioTherapeutics, Inc. has announced that it has received written notice from the United States Food and Drug Administration (FDA) that it may initiate a Phase III clinical trial in the United States of its lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD), for the treatment of Gaucher Disease, a lysosomal storage disorder in humans.
› Verified 9 days ago
| Entity Name | St. Agnes Healthcare, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144250176 PECOS PAC ID: 9830092733 Enrollment ID: O20040128001146 |
News Archive
The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
In findings never before seen in melanoma, a novel combination therapy was found to be highly effective at treating patients with skin metastases, new research from UC Davis has shown.
Protalix BioTherapeutics, Inc. has announced that it has received written notice from the United States Food and Drug Administration (FDA) that it may initiate a Phase III clinical trial in the United States of its lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD), for the treatment of Gaucher Disease, a lysosomal storage disorder in humans.
› Verified 9 days ago
| Entity Name | Antoniades Spine L.l.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992962153 PECOS PAC ID: 0042387037 Enrollment ID: O20080917000055 |
News Archive
The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
In findings never before seen in melanoma, a novel combination therapy was found to be highly effective at treating patients with skin metastases, new research from UC Davis has shown.
Protalix BioTherapeutics, Inc. has announced that it has received written notice from the United States Food and Drug Administration (FDA) that it may initiate a Phase III clinical trial in the United States of its lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD), for the treatment of Gaucher Disease, a lysosomal storage disorder in humans.
› Verified 9 days ago
| Entity Name | Medstar Medical Group Ii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184046187 PECOS PAC ID: 0547413825 Enrollment ID: O20130117000347 |
News Archive
The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
In findings never before seen in melanoma, a novel combination therapy was found to be highly effective at treating patients with skin metastases, new research from UC Davis has shown.
Protalix BioTherapeutics, Inc. has announced that it has received written notice from the United States Food and Drug Administration (FDA) that it may initiate a Phase III clinical trial in the United States of its lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD), for the treatment of Gaucher Disease, a lysosomal storage disorder in humans.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Spiro B Antoniades, MD Po Box 626, Great River, NY 11739-0626 Ph: (631) 907-2186 | Spiro B Antoniades, MD 2014 S Tollgate Rd Ste 107, Bel Air, MD 21015-6010 Ph: (410) 446-8747 |
News Archive
The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN).
Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.
In findings never before seen in melanoma, a novel combination therapy was found to be highly effective at treating patients with skin metastases, new research from UC Davis has shown.
Protalix BioTherapeutics, Inc. has announced that it has received written notice from the United States Food and Drug Administration (FDA) that it may initiate a Phase III clinical trial in the United States of its lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD), for the treatment of Gaucher Disease, a lysosomal storage disorder in humans.
› Verified 9 days ago
Dr. Charles A. Hartjen, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 615 W Macphail Rd, Suite 210, Bel Air, MD 21014 Phone: 443-643-2082 Fax: 443-643-2088 | |
Donald Burke Haskins, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 1131 Bel Air Rd, Bel Air, MD 21014 Phone: 410-877-1666 Fax: 410-879-9206 | |
Dr. Mark V Clough, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 201 Plumtree Rd, Suite 301, Bel Air, MD 21015 Phone: 410-569-3326 Fax: 410-569-3551 | |
Dr. Raj Yalamanchili, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 510 Upper Chesapeake Dr, Suite 417, Bel Air, MD 21014 Phone: 443-643-3130 Fax: 443-643-3133 | |
Todd J Tredinnick, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 201 Plumtree Rd, Suite 301, Bel Air, MD 21015 Phone: 410-569-3326 Fax: 410-569-3551 | |
William Cook Iv, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 510 Upper Chesapeake Dr, 417, Bel Air, MD 21014 Phone: 443-643-3130 Fax: 443-643-3133 |